These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33146829)

  • 1. Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers.
    Woo JW; Chung YR; Kim M; Choi HY; Ahn S; Park SY
    Cancer Immunol Immunother; 2021 May; 70(5):1365-1378. PubMed ID: 33146829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
    PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
    Chung YR; Kim HJ; Jang MH; Park SY
    Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
    Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
    Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
    Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
    Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.
    Rustamadji P; Wiyarta E; Pramono M; Maulanisa SC
    Asian Pac J Cancer Prev; 2024 May; 25(5):1607-1613. PubMed ID: 38809632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
    Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
    PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
    Kim M; Choi HY; Woo JW; Chung YR; Park SY
    Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
    Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
    Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
    Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
    Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.